Back to OfferingsDiscover How Pathways Can Shift Oncologists' Initial Brand Preferences in Up to 50% of Cases
In the ever-evolving landscape of oncology treatment, clinical pathways are becoming increasingly influential. Our 2023 Oncology Clinical Pathways Report offers unprecedented insights into how these pathways are reshaping treatment decisions and brand preferences.
Our comprehensive study reveals that provider pathways can exert an influence comparable to brand preferences in treatment selection for certain tumors, underscoring the critical importance of understanding and leveraging these pathways in your market access strategy. While payer pathways demonstrate a more modest impact, they still play a significant role in shaping treatment decisions. Our research shows that payer pathways are generally half as influential as provider pathways, yet their impact cannot be overlooked in a comprehensive market strategy.
Our report goes beyond surface-level analysis to provide you with a nuanced understanding of the oncology landscape. We offer a detailed breakdown of pathway influence across four key tumor types:
- Chronic lymphocytic leukemia
- Multiple myeloma
- Renal cell carcinoma
- Breast cancer
The strength of our research stems from our robust research methodology. We've surveyed 130 oncologists and conducted 17 additional qualitative interviews with oncologists and pathway developers. Our innovative forced-choice methodology allows us to quantify pathway impact with unprecedented precision, giving you confidence in the data that will drive your strategic decisions.
Schedule a brief call with Ramon today for more information about the upcoming and expanded 2024 Oncology Clinical Pathways Report. Stay ahead of the curve and make informed decisions that drive your brand's success.
